THERAPY DOSSIER · th-a94bd9a75c39

Human umbilical cord mesenchymal stem cells modified with an adenoviral decorin vector (MSCs.DCN)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02865031 ↗PHASE1/PHASE2completed

Intravitreal Decorin Preventing Proliferative Vitreoretinopathy in Perforating Injuries: a Pilot Study

Proliferative Vitreoretinopathy

Enrolment: 15 · Results not recorded

NCT03924544 ↗PHASE1unknown

Decorin as an Antifibrotic Agent in Sub Scleral Trabeculectomy: A Pilot Study

Primary Open-angle Glaucoma

Enrolment: 52 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29976507 ↗2018Reported benefit

Decorin-Modified Umbilical Cord Mesenchymal Stem Cells (MSCs) Attenuate Radiation-Induced Lung Injuries via Regulating Inflammation, Fibrotic Factors, and Immune Responses.

MouseRadiationC57BL/6MaleIntravenous engraftment6 hours after irradiation (acute phase) or 28 days after irradiation (later pha…

Model: Experimental mouse model of radiation-induced lung injury following gamma irradiation

Both mesenchymal stem cell treatments reduced lymphocyte infiltration, apoptosis and later fibrosis, with decorin-modified cells clearly more effective, and treatment at 6 hours produced stronger responses than treatment at 28 days.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…